Blepharitis: a rare side effect related to cetuximab in patient with colorectal cancer

Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which competitively inhibits the binding of epidermal growth factor (EGF) and other ligands were approved for metastatic colon cancer in 2004.1 Skin toxicity is the most important side effect of cetuximab administration, but blephar...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2019-08, Vol.12 (8), p.e231774
Main Authors: Manthri, Sukesh, Chakraborty, Kanishka
Format: Article
Language:English
Subjects:
Adenocarcinoma
Administration, Topical
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Blepharitis - chemically induced
Blepharitis - diagnosis
Blepharitis - drug therapy
Cancer therapies
Case reports
Cetuximab - adverse effects
Cetuximab - therapeutic use
Collaboration
Colorectal cancer
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Epidermal growth factor
Female
Health surveillance
Humans
Images In
Immunotherapy
Inflammation
Metastasis
Middle Aged
Monoclonal antibodies
Neoplasm Metastasis
Patients
Targeted cancer therapy
Toxic Optic Neuropathy - etiology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which competitively inhibits the binding of epidermal growth factor (EGF) and other ligands were approved for metastatic colon cancer in 2004.1 Skin toxicity is the most important side effect of cetuximab administration, but blepharitis as ocular toxicity was reported in
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2019-231774